Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials
出版年份 2018 全文链接
标题
Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 20, Issue 7, Pages 1755-1761
出版商
Wiley
发表日期
2018-02-16
DOI
10.1111/dom.13260
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes
- (2017) Yingying Yang et al. MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
- (2017) Satish K. Garg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
- (2017) Paresh Dandona et al. Lancet Diabetes & Endocrinology
- Diabetic Ketoacidosis With Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes
- (2016) Anne L. Peters et al. DIABETES CARE
- The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes
- (2016) Helena W. Rodbard et al. DIABETES CARE
- Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes
- (2016) Nitesh D. Kuhadiya et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
- (2015) Arthur T. Sands et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
- (2015) Robert R. Henry et al. DIABETES CARE
- Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry
- (2015) Kellee M. Miller et al. DIABETES CARE
- Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
- (2015) T. R. Pieber et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
- (2014) Robert R. Henry et al. DIABETES CARE
- Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
- (2014) Jane L. Chiang et al. DIABETES CARE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started